7 Undervalued Biotechnology Stocks for Thursday, November 07
Discover the top 7 undervalued Biotechnology stocks for Thursday, November 07 based on AAII’s Stock Grades.Aneeqa Nadeem
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Commentary & Analysis
4 Undervalued Biotechnology & Medical Research Stocks for Friday, September 06
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Friday, September 06 based on AAII’s Stock Grades.Jenna Brashear
4 Undervalued Biotechnology & Medical Research Stocks for Tuesday, August 06
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Tuesday, August 06 based on AAII’s Stock Grades.Eunice Kim
5 Undervalued Biotechnology & Medical Research Stocks for Thursday, June 20
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Thursday, June 20 based on AAII’s Stock Grades.Grace Malone
5 Undervalued Biotechnology & Medical Research Stocks for Tuesday, March 26
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Tuesday, March 26 based on AAII’s Stock Grades.Jack Gilleland
Financial Summary
| Share Statistics | PHIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $12.1 | $251.9 | 7% |
|
| Shares Out (Mil) | 11.6 | 50.8 | 23% |
|
| Institutional Ownership | 94.1% | 92.0% | 64% |
|
| Float (Mil) | 11.5 | 40.5 | 21% |
|
| Beta | 0.81 | 0.95 | 48% |
|
| Avg Daily Volume (000s) | 261 | 447 | 49% |
|
| Price Change (52-week) |
(59.1%) | 54.2% | 13% |
|
| Growth | PHIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | 0.2% | (9.8%) | 40% |
|
| EPS (5yr) | 62.9% | 16.3% | 96 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (56.7%) | (15.6%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.360) | ($1.375) | ($0.860) | |
| Month Ago EPS | ($0.360) | ($1.375) | ($0.860) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 2 | |
| Three Months Ago EPS | ($0.235) | ($0.950) | ($0.620) | |
| Year/Year Chg | 4.3% | (5.4%) | na | |
| Financials | PHIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($11) | ($43) | 29% |
|
| EPS (TTM) | ($1.399) | ($1.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($11) | ($30) | 19% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($5) | $182 | 2% |
|
| Valuation | PHIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.73 | 2.60 | 15% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | PHIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (70.9%) | (49.7%) | 8% |
|
| ROE | (76.4%) | (55.4%) | 12% |
|
| Liabilities to Assets | 5.5% | 30.3% | 3% |
|
| F-Score | 2 | 3 | 7% |
|
Phio Pharmaceuticals Corp. did not pass any screens on 7/30/2026.
